⚠️ FDA Notice: Compounded GLP-1 medications are not FDA-approved. The FDA is currently proposing to exclude semaglutide, tirzepatide, and liraglutide from the 503B bulks list.
Pipeline

DMR: The Procedure That May Let You Stop GLP-1 Without Regaining

· 8 min read

The biggest unresolved question in GLP-1 therapy isn't whether the drugs work — it's what happens when you stop. Roughly 70% of patients discontinue GLP-1 medications within 18 months, and most regain about two-thirds of the weight they lost within a year of stopping. A procedure called duodenal mucosal resurfacing (DMR) may change that equation entirely.

What DMR Actually Is

DMR is an investigational outpatient endoscopic procedure that uses controlled heat to ablate (burn away) the inner lining of the duodenum — the first section of the small intestine, immediately below the stomach. The procedure takes approximately 60 minutes, requires no incisions, and is performed under sedation. There is no hospital stay.

The theory behind DMR centers on the duodenum's role in metabolic hormone signaling. In people with obesity, the duodenal lining can become dysfunctional, disrupting the hormonal signals that regulate blood sugar, appetite, and fat metabolism. By ablating the damaged tissue and allowing new, healthier mucosal tissue to regenerate, DMR appears to "reset" the gut's metabolic signaling — potentially allowing the body to maintain weight loss without ongoing medication.

Think of it like this: GLP-1 medications mimic the hormones your gut should be producing. DMR tries to fix the gut so it produces those signals on its own again.

The REMAIN-1 Trial: First Randomized Evidence

The REMAIN-1 trial, sponsored by Fractyl Health, is the pivotal study evaluating DMR specifically for GLP-1 weight maintenance. The program has enrolled more than 300 participants and is fully randomized.

At Digestive Disease Week (DDW) 2026, held May 2–5 in Chicago, lead investigator Shelby Sullivan, MD, of Dartmouth Health presented the midpoint cohort results — the first blinded, randomized, sham-controlled data on DMR for post-GLP-1 weight maintenance.

The study design is rigorous. Participants who had lost at least 15% of body weight on tirzepatide were randomized 2:1 to receive either actual DMR ablation or a sham procedure. Critically, patients in both groups were intubated and had an endoscope advanced to the small bowel — only the treatment group received the actual ablation. This makes it a true blinded comparison, controlling for the placebo effect of undergoing a procedure.

Key Results

The data presented at DDW 2026 showed that patients treated with DMR maintained over 80% of their GLP-1 weight loss at 6 months after stopping tirzepatide, with benefits appearing to grow over time. The sham group, by contrast, showed the expected pattern of progressive weight regain.

Earlier open-label data from the same trial, presented at Obesity Week 2025, had shown promising 3-month results. The 15 DMR-treated participants in that cohort had a mean pre-GLP-1 weight of 104.8 kg, lost an average of 23.8% of body weight on tirzepatide, and largely maintained that loss through 3 months post-procedure. Adverse events were minor and consistent with routine upper endoscopy — no serious safety signals.

Why the Weight Regain Problem Matters So Much

The regain issue isn't academic. Studies consistently show that approximately two-thirds of weight lost on GLP-1 therapy is regained within one year of discontinuation. The biological mechanisms are straightforward: GLP-1 medications suppress appetite, slow gastric emptying, and modulate insulin signaling. When the drug stops, those effects stop. The body's set-point mechanisms kick back in.

This creates a practical dilemma. Many patients stop GLP-1s due to cost, side effects, insurance changes, or simply not wanting to take a medication indefinitely. As our analysis of real-world GLP-1 outcomes showed, 70% dropout rates are the norm, not the exception. And with the FDA moving to end compounded GLP-1 access, some patients will be forced off affordable compounded versions without being able to afford brand-name alternatives.

DMR vs. Other Off-Ramp Strategies

DMR isn't the only approach being studied for maintaining GLP-1 weight loss after stopping therapy. Other strategies include:

Dose reduction protocols. Gradual tapering rather than abrupt discontinuation. Some observational data suggests this slows regain, but doesn't prevent it long-term. There's no standardized protocol.

Combination with resistance training and high-protein diets. The lean body mass preservation data suggests that patients who maintain muscle mass during GLP-1 therapy may have higher resting metabolic rates that partially offset regain. But this hasn't been validated in controlled discontinuation studies.

Intermittent dosing. Some clinicians are experimenting with every-other-week or monthly dosing as a maintenance strategy. This is purely anecdotal — no controlled data exists.

What makes DMR unique is that it's a one-time procedure designed to create a durable biological change, not a behavioral or dosing workaround. If the randomized data holds, it would be the first intervention specifically validated for post-GLP-1 weight maintenance.

Timeline to Availability

DMR is not yet FDA-approved. Here's the expected timeline:

Topline six-month pivotal cohort data from the full REMAIN-1 program is expected in early Q4 2026. If positive, Fractyl Health plans to file for a premarket approval (PMA) with the FDA later that year. Assuming a standard FDA review cycle, the earliest DMR could reach the US market would be late 2027 or 2028.

Previous pooled data from more than 100 patients with type 2 diabetes had already shown that DMR maintained body weight loss up to 48 weeks post-procedure, providing a foundation for the current obesity-focused REMAIN-1 program.

What Patients Should Know Right Now

DMR is investigational. You cannot get this procedure outside of a clinical trial. If you're currently on GLP-1 therapy and concerned about what happens when you stop, the actionable steps today are:

Prioritize resistance training and adequate protein intake during GLP-1 therapy to preserve lean mass. Discuss any planned discontinuation with your prescriber — abrupt stops tend to produce faster regain than gradual dose reduction. If you're interested in the REMAIN-1 trial, Fractyl Health's clinical trial information is available through ClinicalTrials.gov (search "REMAIN-1 DMR").

The weight regain problem is real, but the science is catching up. DMR represents the most advanced attempt to solve it — and if the full randomized data confirms what the midpoint results suggest, it could fundamentally change how we think about the duration of GLP-1 therapy.

Compare GLP-1 Providers & Pricing

See current pricing from verified telehealth providers offering GLP-1 medications.

Compare Providers →

Sources

Related Articles

Data

Why Real-World GLP-1 Results Are 5× Worse Than Clinical Trials

 Clinical

The Muscle Loss Problem: GLP-1 and Lean Body Mass in 2026